JPH03181407A - Agent and method for sterilizing medical waste - Google Patents
Agent and method for sterilizing medical wasteInfo
- Publication number
- JPH03181407A JPH03181407A JP32224489A JP32224489A JPH03181407A JP H03181407 A JPH03181407 A JP H03181407A JP 32224489 A JP32224489 A JP 32224489A JP 32224489 A JP32224489 A JP 32224489A JP H03181407 A JPH03181407 A JP H03181407A
- Authority
- JP
- Japan
- Prior art keywords
- component
- medical waste
- reaction
- sterilization
- treatment agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002906 medical waste Substances 0.000 title claims abstract description 49
- 230000001954 sterilising effect Effects 0.000 title claims description 73
- 238000000034 method Methods 0.000 title claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 54
- 238000006243 chemical reaction Methods 0.000 claims abstract description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000006104 solid solution Substances 0.000 claims abstract description 19
- 239000011398 Portland cement Substances 0.000 claims abstract description 7
- 229910052925 anhydrite Inorganic materials 0.000 claims abstract description 7
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims abstract description 7
- 125000005843 halogen group Chemical group 0.000 claims abstract description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 6
- 239000011707 mineral Substances 0.000 claims abstract description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000011575 calcium Substances 0.000 claims abstract description 4
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 4
- 229910052602 gypsum Inorganic materials 0.000 claims abstract 7
- 239000010440 gypsum Substances 0.000 claims abstract 7
- 238000004659 sterilization and disinfection Methods 0.000 claims description 52
- 238000012545 processing Methods 0.000 claims description 22
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- 150000004683 dihydrates Chemical class 0.000 claims description 5
- 235000010755 mineral Nutrition 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 229910052782 aluminium Inorganic materials 0.000 claims description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 3
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 3
- 150000002823 nitrates Chemical class 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical class [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 2
- 150000001735 carboxylic acids Chemical class 0.000 claims description 2
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- ZOMBKNNSYQHRCA-UHFFFAOYSA-J calcium sulfate hemihydrate Chemical compound O.[Ca+2].[Ca+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O ZOMBKNNSYQHRCA-UHFFFAOYSA-J 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims 1
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 abstract description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 abstract 4
- 229910052593 corundum Inorganic materials 0.000 abstract 3
- 229910001845 yogo sapphire Inorganic materials 0.000 abstract 3
- 229910052681 coesite Inorganic materials 0.000 abstract 2
- 229910052906 cristobalite Inorganic materials 0.000 abstract 2
- 239000000377 silicon dioxide Substances 0.000 abstract 2
- 235000012239 silicon dioxide Nutrition 0.000 abstract 2
- 229910052682 stishovite Inorganic materials 0.000 abstract 2
- 229910052905 tridymite Inorganic materials 0.000 abstract 2
- 150000008064 anhydrides Chemical class 0.000 abstract 1
- 229910001634 calcium fluoride Inorganic materials 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 238000009434 installation Methods 0.000 abstract 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 abstract 1
- 229910000096 monohydride Inorganic materials 0.000 abstract 1
- 238000006703 hydration reaction Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 230000036571 hydration Effects 0.000 description 6
- 239000002699 waste material Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 244000000010 microbial pathogen Species 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 229910001653 ettringite Inorganic materials 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002562 urinalysis Methods 0.000 description 3
- -1 2CaO-8io Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 230000020169 heat generation Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- BNGXYYYYKUGPPF-UHFFFAOYSA-M (3-methylphenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].CC1=CC=CC(C[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 BNGXYYYYKUGPPF-UHFFFAOYSA-M 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 235000019738 Limestone Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 235000011126 aluminium potassium sulphate Nutrition 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 229910001570 bauxite Inorganic materials 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000010436 fluorite Substances 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 1
- YHGPYBQVSJBGHH-UHFFFAOYSA-H iron(3+);trisulfate;pentahydrate Chemical compound O.O.O.O.O.[Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O YHGPYBQVSJBGHH-UHFFFAOYSA-H 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 229910000360 iron(III) sulfate Inorganic materials 0.000 description 1
- 239000006028 limestone Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 229940050271 potassium alum Drugs 0.000 description 1
- GNHOJBNSNUXZQA-UHFFFAOYSA-J potassium aluminium sulfate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GNHOJBNSNUXZQA-UHFFFAOYSA-J 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
Landscapes
- Apparatus For Disinfection Or Sterilisation (AREA)
- Curing Cements, Concrete, And Artificial Stone (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
【発明の詳細な説明】
「産業−ヒのＩＩＩ用分野−１
本発明は、注射針、ランセット、メス、プｊ −ゼ 、
包帯、点滴輸血用容器、試験管、検尿コツプ、実験動物
等の医療廃棄物の滅菌処理方法とこれに用いられる処理
剤に関する。[Detailed Description of the Invention] "Industry - Field III - 1 The present invention is applicable to injection needles, lancets, scalpels, needles, bandages, drip transfusion containers, test tubes, urinalysis tips, laboratory animals, etc. This invention relates to a method for sterilizing medical waste and a processing agent used therein.
「従来技術とその課題」
近年、医療器材の注射針、ランセット、メス、ガーゼ、
包帯、点滴輸血用容器、試験管、検尿コツプ、実験動物
等は感染予防のためにディスボザブル製品等に変わりつ
つあり、またこうした注射針の処理や廃棄場所の環境汚
染の面から、医療廃棄物に対する処理対策、特に廃棄に
際しての滅菌処理が重要な課題となっている。"Prior art and its issues" In recent years, medical equipment such as injection needles, lancets, scalpels, gauze,
Bandages, intravenous blood transfusion containers, test tubes, urinalysis tips, laboratory animals, etc. are being replaced with disposable products to prevent infection, and in view of the environmental pollution of the disposal and disposal sites of these injection needles, there is a need to dispose of medical waste. Processing measures, especially sterilization during disposal, are becoming important issues.
ところで、日本薬局法では滅菌法として加熱滅菌法、ろ
過滅菌法、照射滅菌法、化学的滅菌伏が定められており
、河えば医療器材のうちプラスデック類には放射ｗＡ（
γ線）照射による滅菌が、金属類やガラス類にはオート
クレーブ中での滅菌（高庄蒸気滅菌）が、また不織布類
にはエチレンオキサイド等の殺菌性ガスによる滅菌がそ
れぞれ好適とされている。By the way, the Japanese Pharmacy Law stipulates heat sterilization, filtration sterilization, irradiation sterilization, and chemical sterilization as sterilization methods.
Sterilization by irradiation (gamma rays) is preferred, sterilization in an autoclave (high steam sterilization) is preferred for metals and glass, and sterilization by sterilizing gas such as ethylene oxide is preferred for nonwoven fabrics.
しかしながら、−１：、５ｉｌ！滅菌注においては以下
に述べる不都合がある。However, -1:,5il! Sterile injections have the following disadvantages.
放射線照射を行うには高価な設備か必要であり、したが
って現状では個人開業医などの小さな医療施設にまで放
射線照射設備が行き渡るには至っていない。Expensive equipment is required to perform radiation irradiation, and therefore radiation irradiation equipment is not currently available in small medical facilities such as private practitioners.
オートクレーブを坩いるなどの加熱滅菌法は現在最もよ
く行われている方法ではあるものの、処理するにあたっ
てオートクレーブ等の器材に廃棄物を投入し、処裡後に
取り出すといった手間がかかり、また設備費ｍ、維持費
ｍが高価であり、しかも例えば使用済みの注射針を廃棄
する場合、投入あるいは取り出しの際誤って指を刺傷す
る恐れかある。Although heat sterilization methods such as autoclaving are currently the most commonly used methods, they require time and effort to put the waste into equipment such as an autoclave and take it out after treatment, and they also require equipment costs, The maintenance cost m is high, and when disposing of used injection needles, for example, there is a risk of accidentally puncturing a finger when inserting or removing the needles.
エヂレンオキサイド等の殺菌性ガスによる滅菌法は、殺
菌性ガスが毒ガスであり取り扱いに十分な注意を要する
ことから、実際に行うには高度な設備と、塾練を必要と
し、小さな医療施設で行うにはやはり困難である。Sterilization using a sterilizing gas such as ethylene oxide is a poisonous gas and requires great care when handling, so it requires advanced equipment and training to perform in practice, and can only be carried out in small medical facilities. It is still difficult to do.
このように上記の滅菌法にあってはいずれら不都合があ
り、よって高度な設備を必要とせず、しかも処理にあた
っての操作が簡便な医療廃棄物の滅菌方法の提供が望ま
れている。As described above, each of the above sterilization methods has disadvantages, and therefore, it is desired to provide a method for sterilizing medical waste that does not require sophisticated equipment and is easy to operate during processing.
「課題を解決するための手段」
本発明者等は、医療廃棄物の滅菌処理方法として発熱性
セメントの水和反応による熱を利用することに着目し、
以下に示すような滅菌用処理に好適な処理剤とこれを用
いてなる処理方法を提供することによって上記課題を解
決した。"Means for Solving the Problem" The present inventors focused on the use of heat generated by the hydration reaction of pyrogenic cement as a method for sterilizing medical waste.
The above problems have been solved by providing a processing agent suitable for sterilization treatment and a processing method using the same as shown below.
すなわち本発明の請求項１ないし６記載の医療廃棄物滅
菌用処理剤は、３ ｃａｏ −ｓ ｉｏ を固溶体、２
Ｃａｏ ・Ｓ ｉｏ を固溶体、２ Ｃａｏ−Ｆｅｇ
ｏ ３〜６ Ｃａｏ ” ２ Ａ Ｑ＊０３” Ｆ ｅ
ｔｏ ３系固溶体、その他からなるポルトランドセメン
トクリンカ−鉱物（成分１）と、１１ＣａＯ７ＡｈＯｓ
・ｃａＸ ｔ （ここでＸはハロゲン原子を表わす。）
、１２ＣａＯ・７Ａ（！ｔｏ３゜ＣａＯ’Ａ１２ｔＯｔ
、 ３ ＣａＯ’３ Ａ（！ｔＯ＋”ＣａＳ ０４およ
び３ ｃａｏ ’３ Ａ１２ｔＯ３’ＣａＦ ｔよりな
る群から選ばれた少なくとも１種（成分２）と、無水石
膏、半水石膏および二水石膏よりなる群から選ばれた少
なくとも１種（成分３）を主成分とするものである。That is, the treatment agent for medical waste sterilization according to claims 1 to 6 of the present invention includes 3 cao -s io as a solid solution and 2 cao -s io as a solid solution.
Cao ・S io as a solid solution, 2 Cao-Feg
o 3～6 Cao ” 2 A Q*03” F e
Portland cement clinker mineral (component 1) consisting of to 3-based solid solution and others, and 11CaO7AhOs
・caX t (Here, X represents a halogen atom.)
, 12CaO・7A(!to3゜CaO'A12tOt
, 3 CaO'3 A(!tO+"CaS 04 and 3cao'3A12tO3'CaF t); and at least one component (component 2) selected from the group consisting of anhydrite, hemihydrate, and dihydrate. The main component is at least one type (component 3) selected from the following.
また請求項７ないし１２紀載の医療廃棄物の滅菌処理方
法は、請求項１ないし６記載の医療廃棄物滅菌用処理剤
と水との反応を起こし、これらの反応による反応熱とア
ルカリ性とにより医療廃棄物を滅菌するものである。Further, the method for sterilizing medical waste according to claims 7 to 12 involves causing a reaction between the treatment agent for medical waste sterilization according to claims 1 to 6 and water, and by the reaction heat and alkalinity caused by these reactions. It sterilizes medical waste.
以下、この発明の詳細な説明する。The present invention will be described in detail below.
本発明の請求項１記載の医療廃棄物滅菌用処理剤（以下
、処理剤と略称する）は、成分ｌとして３ＣａＯ−６ｉ
Ｏ２固溶体、２ＣａＯ−８ｉｏ、固溶体、２ Ｃａｏ
Ｐ ｅｔｏ ｙ〜６ Ｃａｏ ＋ ２ Ａ （！ｔ０
３・Ｆｅｔｏ ３系固溶体、その他からなるポルトラン
ドセメントクリンカ−鉱物を含有し、成分２として１１
Ｃ＋ａ、０・７Ａ（ｌｔＯｚ・ＣａＸ２（ここでＸはハ
ロゲン原子を表わす。）、１２ｃａｏ’７Ａｆ２，０３
．ＣａＯ”Ａｌ２ｔＯ３゜３ ＣａＯ・３ ＡＣｔＯ３
・ＣａＳ Ｏ−および３ＣａＣ１３ＡＱ、ｖＯｓ・ｃａ
Ｆ２よりなる群から選ばれた少なくとも１種を含有し、
成分３として無水石膏、半水石膏および二水石膏よりな
る群から選ばれた少なくとも１種を含有したちのである
。The treatment agent for medical waste sterilization (hereinafter abbreviated as treatment agent) according to claim 1 of the present invention comprises 3CaO-6i as a component 1.
O2 solid solution, 2CaO-8io, solid solution, 2 Cao
P etoy ~ 6 Cao + 2 A (!t0
Contains Portland cement clinker minerals consisting of 3-Feto 3 solid solution and others, and contains 11 as component 2.
C+a, 0.7A (ltOz.CaX2 (here, X represents a halogen atom), 12cao'7Af2,03
．． CaO”Al2tO3゜3 CaO・3 ACtO3
・CaS O- and 3CaC13AQ, vOs・ca
Contains at least one species selected from the group consisting of F2,
Component 3 contains at least one selected from the group consisting of anhydrite, hemihydrate and dihydrate.
このような処理剤■において成分ｌと成分２の重量比は
、ｌ：９９〜９９：１１成分１と成分２の重量の和と成
分３との重量との比が１００：３〜ｌ：３４であるのが
好ましい。なお成分２は、結晶質、非晶質（含むガラス
質）のうち少なくとも一種を含むものである。In such a treatment agent (2), the weight ratio of component 1 to component 2 is 1:99 to 99:11, and the ratio of the sum of the weights of component 1 and 2 to the weight of component 3 is 100:3 to 1:34. It is preferable that Note that component 2 contains at least one of crystalline and amorphous (including glassy) materials.
このような処理剤は、成分ｌおよび成分２がアルカリ性
を有するものであるから、成分３の配合量などを適宜謂
整することにより、水と反応することによってｐＨ１２
程度までのアルカリ性を雫するものとなるばかりか、ｐ
Ｈを成分３の添加により自由に調節できる。In such a treatment agent, component 1 and component 2 have alkalinity, so by adjusting the blending amount of component 3 as appropriate, the pH can be lowered to 12 by reacting with water.
Not only does it reduce alkalinity to a certain degree, but it also causes p.
H can be freely adjusted by adding component 3.
またこの処理Ｍは、水と反応すると、成分２、すなわち
目ＣａＯ・７ Ａ （ｔｏ ３・ｃ ａＸ ２、＋２ｃ
、１０ ・７ ＡＯ，ｔＯｓ、 Ｃａｏ−Ａ１２ｔＯ
ｓ、 ３ Ｃａｏ ・３ Ａ１２ｔＯ３”Ｃａ５Ｏ＊お
よび３ ＣａＯ ・３ ＡＣｔＯ３・（、＋Ｆ ｘから
選ばれたものが水にただちに溶解し、成分１のけい酸カ
ルシウム相の溶解に上り生成した水酸化カルシウムと反
応して非常に早期にアルミン酸−硫酸カルシウム水和物
を生成し、その際水和熱を生じろものとなる。この水和
熱の発熱量は、処理剤と水との量や各成分の配合比によ
って特に成分の配合”１１合の増減により適宜調整可能
であるが、例えば９０℃以−ヒの発熱を７分以−ヒ持続
し得ろものであり、かつ６０℃以上の発熱を３０分以上
持続し得るものである。In addition, when this treatment M reacts with water, component 2, namely CaO・7 A (to 3・caX 2, +2c
, 10 ・7 AO,tOs, Cao-A12tO
s, 3 Cao ・3 A12tO3"Ca5O* and 3 CaO ・3 ACtO3 The reaction generates aluminic acid-calcium sulfate hydrate very quickly, which generates heat of hydration.The calorific value of this heat of hydration depends on the amount of treatment agent and water and the amount of each component. This can be adjusted appropriately depending on the blending ratio, especially by increasing or decreasing the ingredient composition. It can last for more than minutes.
また、処理剤と水との反応によって得られた水和物は、
液相中のイオン濃度の変化に応じてエトリンジヤイトに
変化し、早期に高強度の硬化体となる。この硬化体は、
その微細構造内に病原微生物等を吸着するものとなり、
しかも水和により生成するエトリンジヤイトがこれを封
じ込めろものとなる。そして、このような吸着作用によ
り処理剤では、水和による発熱にあたって蒸気や異臭の
発生が抑制される。In addition, the hydrate obtained by the reaction between the treatment agent and water is
It changes to ettringite in response to changes in the ion concentration in the liquid phase, quickly becoming a hardened product with high strength. This hardened body is
It adsorbs pathogenic microorganisms within its fine structure,
Moreover, the ettringite produced by hydration can contain this. Due to such an adsorption effect, the treatment agent suppresses the generation of steam and off-odor when it generates heat due to hydration.
またこの処理剤には、適宜ナトリウム、カリウム カル
シウム、アルミニウム、鉄、マンガンおよびマグネシウ
ムの硫酸塩、硝酸塩、炭酸塩およびそれらの複塩よりな
る群から選ばれた少なくとも１種が成分４として配合さ
れる。この成分４は、後述する水和反応時において便化
速度を調整するものであり、具体的には硫酸第二鉄、硫
酸第一鉄、硫酸アルミニウム、カリミョウバン、焼ミョ
ウバン、炭酸カルシウム、硫酸マンガン、硝酸アルミニ
ウム、硫酸ナトリウム、硫酸カリウム等が挙げられる。In addition, at least one member selected from the group consisting of sodium, potassium, calcium, aluminum, iron, manganese, and magnesium sulfates, nitrates, carbonates, and double salts thereof is blended as component 4 in this treatment agent. . This component 4 adjusts the fecalization rate during the hydration reaction described below, and specifically includes ferric sulfate, ferrous sulfate, aluminum sulfate, potassium alum, calcined alum, calcium carbonate, and manganese sulfate. , aluminum nitrate, sodium sulfate, potassium sulfate, and the like.
またこのｊ成分４の配合量としては、成分ｌ〜３の重量
の和と成分４の重量との比が前者１００に対して後者２
０以下とするのが好ましい。In addition, as for the blending amount of component j 4, the ratio of the sum of the weights of components 1 to 3 and the weight of component 4 is 100 for the former and 2 for the latter.
It is preferable to set it to 0 or less.
さらに、この処理剤には、適宜オキジカルボン酸。カル
ボン酸およびそれらの塩類よりなる群から選ばれた少な
くとも１１が、成分５として配合される。この成分５も
、成分４と同様に後述する水和反応時において硬化速度
を調整するものである。この成分５の配合量としては、
成分１〜４の重量の和と成分５の重量との比か前者＋０
０に対して後者ＩＯ以下とするのが好ましい。Furthermore, this treatment agent contains an oxydicarboxylic acid as appropriate. At least 11 selected from the group consisting of carboxylic acids and their salts are blended as component 5. Similar to component 4, this component 5 also adjusts the curing rate during the hydration reaction described later. The amount of component 5 is as follows:
The ratio between the sum of the weights of components 1 to 4 and the weight of component 5, or the former + 0
It is preferable that the latter IO be less than 0.
このような処理剤においては、各成分の状態として粉末
状、粒状あるいはこれらの屍合状態、さらには錠剤Ｉ等
の任意の形状に成形した状態で使甫することが可能であ
る。In such a processing agent, each component can be used in the form of powder, granules, or a combination thereof, or even in the form of an arbitrary shape such as a tablet I.
次に、このような処理剤を用いた医療廃棄物の滅菌方法
について説明する。Next, a method for sterilizing medical waste using such a processing agent will be explained.
この滅菌処理方法が適用される廃棄物としては、使用済
みの注射針、ランセット、メス、シャーレ、ピペット、
ガーゼ、包帯、点滴輸血用容器、試験管、検尿コツプ、
実験動物などが挙げられろ。そして、このような医療廃
棄物を滅菌するには、例えば予め上記処理剤を処理容器
内に入れておき、この容器内に処理前の廃棄物を入れた
後、処理容４内の処理剤に水を加えろ。Waste to which this sterilization method is applied includes used syringe needles, lancets, scalpels, petri dishes, pipettes,
Gauze, bandages, drip transfusion containers, test tubes, urinalysis tips,
Examples include experimental animals. In order to sterilize such medical waste, for example, the above-mentioned processing agent is placed in a processing container in advance, and after the waste to be processed is placed in this container, the processing agent in the processing container 4 is sterilized. Add water.
すると、処理剤が水和反応を起こして発熱し、さらに成
分ｌ、２の水和物によって処理容器内か高アルカリ性と
なる。そして、これにより処理容器内では、高点および
アルカリ性により医療廃棄物が滅菌される。また、処理
剤中の成分２がエトリンジヤイトに変化し、早期に高強
度の硬化体となることから、医ｆｔ１１１ｉ！棄物が硬
化体に固定され、特に十分量の処理剤か■意されて処理
された場合には、医療廃棄物が硬化体中に完全封じ込め
られる。またこの場合、発熱やアルカリの発生に伴う蒸
気や臭気の発生も、硬化体の吸着作用によりほとんど抑
えられることから、処理容器の気密性などについての心
配か全くなく、処理容器の構造が簡単で安価に製造でき
る。Then, the processing agent causes a hydration reaction and generates heat, and the inside of the processing container becomes highly alkaline due to the hydrates of components 1 and 2. As a result, the medical waste is sterilized in the processing container due to high points and alkalinity. In addition, component 2 in the treatment agent changes to ettringite and quickly becomes a high-strength hardened product, so medical ft111i! The medical waste is fixed in the cured body and, especially when treated with a sufficient amount of treatment agent, the medical waste is completely contained in the cured body. In addition, in this case, the generation of steam and odor due to heat generation and generation of alkali is almost suppressed by the adsorption effect of the hardened material, so there is no need to worry about the airtightness of the processing container, and the structure of the processing container is simple. Can be manufactured cheaply.
この場合に処理剤の発熱の度合は、各成分の種類やその
状態、積、成分（純度）および水の積などによって調整
可能であり、４０−１０００程度、好ましくは４０〜９
０°Ｃ程度に廃棄物を加熱し得るよう週整するのが望ま
しい。また処理時間としては、廃棄物の加熱温度によっ
て異なるが、１〜９０分間行うものとされる。In this case, the degree of heat generation of the processing agent can be adjusted by the type of each component, its state, product, product of component (purity) and water, etc., and is about 40-1000, preferably 40-9
It is desirable to condition the waste once a week so that it can be heated to about 0°C. Further, the treatment time varies depending on the heating temperature of the waste, but it is assumed that the treatment is carried out for 1 to 90 minutes.
このような滅菌方法によれば、処理剤と水との反応熱（
水和熱）および水和によって得られるアルカリ性、さら
には反応硬化時における硬化体の吸着作用などにより、
病原微生物を有効に滅菌することができ、よって従来の
放射線（γ線）照射による滅菌や、オートクレーブ中で
の滅菌（高圧蒸気滅菌）、エチレンオキサイド等の殺菌
性ガスによる滅菌に比べて高価な設備を必要とけず、簡
便な操作により容易にＬかｔ１安全かっ寄Ｃ品に帆伸す
ることできる。また、硬化体の吸着作用によって反応時
における蒸気や異臭の発生を抑制することができる。さ
らに、処理前の硬化に伴い被処理物（医り廃棄物）を固
定することができることから、例えば実験動物等を処理
した場合にも、十分な量の処理剤を用い、これを完全に
封じ込めるようにして固化すれば、この固化体をそのま
まで廃棄することができ、したがって被処理物の後処理
を容易に行うことができる。According to such a sterilization method, the heat of reaction between the treatment agent and water (
heat of hydration), alkalinity obtained through hydration, and the adsorption effect of the cured product during reaction curing.
It can effectively sterilize pathogenic microorganisms, and therefore requires more expensive equipment than conventional sterilization using radiation (gamma rays), sterilization in an autoclave (high-pressure steam sterilization), and sterilization using sterilizing gases such as ethylene oxide. It is possible to easily extend L or t1 safely to C product by simple operation. Furthermore, the adsorption effect of the cured product can suppress the generation of steam and off-odor during the reaction. Furthermore, since the material to be treated (medical waste) can be fixed as it hardens before treatment, even when treating laboratory animals, for example, a sufficient amount of treatment agent can be used to completely contain it. By solidifying in this manner, the solidified body can be disposed of as is, and therefore the material to be treated can be easily post-treated.
（実験例） 第１表に示す組成の処理剤を作製した。(Experiment example) A treatment agent having the composition shown in Table 1 was prepared.
以下余白 第 ■ 表 （表中の数値の単位は重量％） なお、この処理剤の作製を以下のようにして行った。Margin below No. ■ table (The units of numerical values in the table are weight%) Note that this processing agent was prepared as follows.
石灰石、ボーキサイト、粘土、ホタル石を配合し粉砕し
て得た調合原料を焼成炉で焼成して得た調合原料を焼成
炉で焼成し、第１表に示した成分ｌと成分２からなる組
成物を得、この組成物を比表面積（ブレーン値） ５２
００ｃｍ”／Ｈに粉砕した。また、これと別に粉砕した
無水石膏（ＣａＳＯ，含有量＝ ９６．２％、比表面積
６２００ｃＩＩ！”／ ｇ ）を上記のとおりに加え、
処理剤を得た。A blended raw material obtained by blending and pulverizing limestone, bauxite, clay, and fluorite is fired in a kiln, and the blended raw material obtained is fired in a kiln to create a composition consisting of component 1 and component 2 shown in Table 1. This composition has a specific surface area (Blane value) of 52
In addition, anhydrite (CaSO, content = 96.2%, specific surface area 6200 cII!''/g), which was crushed separately, was added as above.
A processing agent was obtained.
このようにして得た処理前の、枯草菌を含む標準菌株５
閑種への滅菌効果を以下のようにして調べた。Standard strain 5 containing Bacillus subtilis before treatment obtained in this way
The sterilization effect on free species was investigated as follows.
まず、上記標準菌株をその各菌種について滅菌生理食塩
水で希釈し、これらをそれぞれ滅菌ガーゼに浸して滅菌
シャーレに入れ、これらシャーレに処理剤を充填した。First, each of the above-mentioned standard bacterial strains was diluted with sterile physiological saline, each diluted with sterile gauze and placed in a sterile Petri dish, and the Petri dish was filled with a treatment agent.
次に、このシャーレに水を入れて処理剤と水とを反応さ
せて硬化せしめ、蓋をした後約１日間放置した。その後
、滅菌シャーレ中のガーゼを、処理剤の硬化体を破砕し
ガーゼを分離することにより無菌的に回収し、南画培地
に入れた。Next, water was poured into this petri dish to cause the treatment agent to react with the water to harden it, and after covering it with a lid, it was left to stand for about one day. Thereafter, the gauze in the sterilized Petri dish was recovered aseptically by crushing the hardened body of the treatment agent and separating the gauze, and placed in Nanga medium.
南画培地での菌の発育の有無を調べたところ、５菌種と
も完全滅菌されており、処理剤と水との反応熱とアルカ
リ性とが栄養型閉の滅菌に有効であることが確認された
。When examining the presence or absence of bacterial growth on Nanga medium, all five bacterial species were completely sterilized, confirming that the heat of reaction between the treatment agent and water and alkalinity are effective in sterilizing vegetative molds. .
なお、滅菌時における処理容器内の温度を測定したとこ
ろ、８０℃以−ヒの温度が６分以−ヒ、６０°Ｃ以上の
温度が３０分以上続くことが記録された。In addition, when the temperature inside the processing container during sterilization was measured, it was recorded that the temperature of 80° C. or more continued for more than 6 minutes, and the temperature of 60° C. or more continued for more than 30 minutes.
したがって、エイズウィルスが５８℃の温度にて３０分
間で死滅し、また８０℃の温度では５分間で死滅するこ
とから、本発明の処理剤がエイズウィルスの滅菌にも有
効であることが確認された。Therefore, since the AIDS virus is killed in 30 minutes at a temperature of 58°C and 5 minutes at a temperature of 80°C, it is confirmed that the treatment agent of the present invention is also effective in sterilizing the AIDS virus. Ta.
また、同様にがんウィルスやＢ型肝炎ウィルスの滅菌に
も十分有効であると推測される。It is also presumed to be sufficiently effective in sterilizing cancer viruses and hepatitis B viruses.
「発明の効果」
以上説明したようにこの発明の請求項１〜６記載の医療
廃棄物滅菌用処理剤は、水との反応により発熱するとと
もにアルカリ性を呈するものであり、かつ反応に伴って
硬化するものである。したがってこれを用いることによ
り、その反応熱およびアルカリ性によって病原微生物を
有効に滅菌することができ、よって従来の放射線（γ線
）照射による滅菌や、オートクレーブ中での滅菌（高原
蒸気滅菌）、エチレンオキサイド等の殺菌性ガスによる
滅菌に比べて高価な設備を必要とせず、簡便な操作によ
り容易にしかも安全に処理することできる。"Effects of the Invention" As explained above, the treatment agent for medical waste sterilization according to claims 1 to 6 of the present invention generates heat and becomes alkaline by reaction with water, and hardens with the reaction. It is something to do. Therefore, by using it, pathogenic microorganisms can be effectively sterilized by its heat of reaction and alkalinity, and therefore it can be used in conventional sterilization by radiation (gamma ray) irradiation, sterilization in an autoclave (highland steam sterilization), ethylene oxide sterilization, etc. Compared to sterilization using sterilizing gases such as sterilizers, it does not require expensive equipment and can be processed easily and safely with simple operations.
また請求項７〜Ｉ２記載の滅菌方法にあっては、上記の
処理剤と水との反応によって医療廃棄物を処理するので
、上述したように病原微生物を有効に滅菌することがで
き、また硬化した処理剤の吸着作甫などにより、反応時
における蒸気や異臭の発生を抑制することができろ。さ
らに、処理剤の早期硬化（硬化時間も自由に凋節するこ
とができる）に伴い被処理物（医療廃棄物）を固化せし
めることができろことから、この固化した廃棄物をその
ままで廃棄することが可能となり、また本発明の医療廃
棄物滅菌処理剤と水とを入れた医療廃棄物滅菌処理剤器
は高温ガスの排気対策−１：、複雑化の心配もなく簡単
な構造でよく極めて安価に製造でき、したがって被処理
物の後処理を容易に行うことができる。Furthermore, in the sterilization method according to claims 7 to 12, medical waste is treated by the reaction between the above-mentioned treatment agent and water, so that pathogenic microorganisms can be effectively sterilized as described above, and the By adsorbing the treatment agent, it is possible to suppress the generation of steam and odor during the reaction. Furthermore, as the processing agent hardens early (the curing time can be adjusted freely), the material to be treated (medical waste) can be solidified, so this solidified waste can be disposed of as is. In addition, the medical waste sterilization treatment agent container containing the medical waste sterilization treatment agent and water of the present invention has a simple structure and is extremely effective in preventing high-temperature gas exhaust. It can be manufactured at low cost, and therefore the post-processing of the processed object can be easily performed.
Claims (12)
＿２固溶体、２ＣａＯ・Ｆｅ＿２Ｏ＿３〜６ＣａＯ・２
Ａｌ＿２Ｏ＿３・Ｆｅ＿２Ｏ＿３系固溶体、その他から
なるポルトランドセメントクリンカー鉱物（成分１）と
、１１ＣａＯ・７Ａｌ＿２Ｏ＿３・ＣａＸ＿２（ここで
Ｘはハロゲン原子を表わす。）、１２ＣａＯ・７Ａｌ＿
２Ｏ＿３、ＣａＯ・Ａｌ＿２Ｏ＿３、３ＣａＯ・３Ａｌ
＿２Ｏ＿３・ＣａＳＯ＿４および３ＣａＯ・３Ａｌ＿２
Ｏ＿３・ＣａＦ＿２よりなる群から選ばれた少なくとも
１種（成分２）と、無水石膏、半水石膏および二水石膏
よりなる群から選ばれた少なくとも１種（成分３）を含
有してなる医療廃棄物滅菌用処理剤。(1) 3CaO・SiO_2 solid solution, 2CaO・SiO
_2 solid solution, 2CaO・Fe_2O_3~6CaO・2
Portland cement clinker mineral (component 1) consisting of Al_2O_3/Fe_2O_3 solid solution and others, 11CaO/7Al_2O_3/CaX_2 (where X represents a halogen atom), 12CaO/7Al_
2O_3, CaO・Al_2O_3, 3CaO・3Al
_2O_3・CaSO_4 and 3CaO・3Al_2
Medical waste containing at least one type selected from the group consisting of O_3 and CaF_2 (component 2) and at least one type selected from the group consisting of anhydrite, hemihydrate and dihydrate gypsum (component 3) Processing agent for sterilizing objects.
、 成分１と成分２の重量比が１：９９〜９９：１であり、
成分１と成分２の重量の和と成分３の重量との比が１０
０：３〜１：３４である医療廃棄物滅菌用処理剤。(2) In the treatment agent for medical waste sterilization according to claim 1, the weight ratio of component 1 to component 2 is 1:99 to 99:1,
The ratio of the sum of the weights of component 1 and component 2 to the weight of component 3 is 10
A treatment agent for medical waste sterilization having a ratio of 0:3 to 1:34.
＿２固溶体、２ＣａＯ・Ｆｅ＿２Ｏ＿３〜６ＣａＯ・２
Ａｌ＿２Ｏ＿３・Ｆｅ＿２Ｏ＿３系固溶体、その他から
なるポルトランドセメントクリンカー鉱物（成分１）と
、１１ＣａＯ・７Ａｌ＿２Ｏ＿３・ＣａＸ＿２（ここで
Ｘはハロゲン原子を表わす。）、１２ＣａＯ・７Ａｌ＿
２Ｏ＿３、ＣａＯ・Ａｌ＿２Ｏ＿３、３ＣａＯ・３Ａｌ
＿２Ｏ＿３・ＣａＳＯ＿４および３ＣａＯ・３Ａｌ＿２
Ｏ＿３・ＣａＦ＿２よりなる群から選ばれた少なくとも
１種（成分２）と、無水石膏、平水石膏および二水石膏
よりなる群から選ばれた少なくとも１種（成分３）と、
ナトリウム、カリウム、カルシウム、アルミニウム、鉄
、マンガンおよびマグネシウムの硫酸塩、硝酸塩、炭酸
塩およびそれらの複塩よりなる群から選ばれた少なくと
も１種（成分４）を含有してなる医療廃棄物滅菌用処理
剤。(3) 3CaO・SiO_2 solid solution, 2CaO・SiO
_2 solid solution, 2CaO・Fe_2O_3~6CaO・2
Portland cement clinker mineral (component 1) consisting of Al_2O_3/Fe_2O_3 solid solution and others, 11CaO/7Al_2O_3/CaX_2 (where X represents a halogen atom), 12CaO/7Al_
2O_3, CaO・Al_2O_3, 3CaO・3Al
_2O_3・CaSO_4 and 3CaO・3Al_2
At least one type selected from the group consisting of O_3・CaF_2 (component 2), at least one type selected from the group consisting of anhydrite, gypsum and dihydrate (component 3),
For sterilizing medical waste, containing at least one member (component 4) selected from the group consisting of sulfates, nitrates, carbonates, and double salts thereof of sodium, potassium, calcium, aluminum, iron, manganese, and magnesium. Processing agent.
、 成分１と成分２の重量比が１：９９〜９９：１であり、
成分１と成分２の重量の和と成分３の重量との比が１０
０：３〜１：３４、成分１〜３の重量の和と成分４の重
量との比が前者１００に対して後者２０以下である医療
廃棄物滅菌用処理剤。(4) In the treatment agent for medical waste sterilization according to claim 3, the weight ratio of component 1 to component 2 is 1:99 to 99:1,
The ratio of the sum of the weights of component 1 and component 2 to the weight of component 3 is 10
0:3 to 1:34, and the ratio of the sum of the weights of components 1 to 3 to the weight of component 4 is 100 for the former and 20 or less for the latter.
＿２固溶体、２ＣａＯ・Ｆｅ＿２Ｏ＿３〜６ＣａＯ・２
Ａｌ＿２Ｏ＿３・Ｆｅ＿２Ｏ＿３系固溶体、その他から
なるポルトランドセメントクリンカー鉱物（成分１）と
、１１ＣａＯ・７Ａｌ＿２Ｏ＿３・ＣａＸ＿２（ここで
Ｘはハロゲン原子を表わす。）、１２ＣａＯ・７Ａｌ＿
２Ｏ＿３、ＣａＯ・Ａｌ＿２Ｏ＿３、３ＣａＯ・３Ａｌ
＿２Ｏ＿３・ＣａＳＯ＿４および３ＣａＯ・３Ａｌ＿２
Ｏ＿３・ＣａＦ＿２よりなる群から選ばれた少なくとも
１種（成分２）と、無水石膏、半水石膏および二水石膏
よりなる群から選ばれた少なくとも１種（成分３）と、
ナトリウム、カリウム、カルシウム、アルミニウム、鉄
、マンガンおよびマグネシウムの硫酸塩、硝酸塩、炭酸
塩およびそれらの複塩よりなる群から選ばれた少なくと
も１種（成分４）と、オキシカルボン酸、カルボン酸お
よびそれらの塩類よりなる群から選ばれた少なくとも１
種（成分５）を含有してなる医療廃棄物滅菌用処理剤。(5) 3CaO・SiO_2 solid solution, 2CaO・SiO
_2 solid solution, 2CaO・Fe_2O_3~6CaO・2
Portland cement clinker mineral (component 1) consisting of Al_2O_3/Fe_2O_3 solid solution and others, 11CaO/7Al_2O_3/CaX_2 (where X represents a halogen atom), 12CaO/7Al_
2O_3, CaO・Al_2O_3, 3CaO・3Al
_2O_3・CaSO_4 and 3CaO・3Al_2
At least one type selected from the group consisting of O_3・CaF_2 (component 2), at least one type selected from the group consisting of anhydrite, hemihydrate gypsum, and dihydrate gypsum (component 3),
At least one member selected from the group consisting of sodium, potassium, calcium, aluminum, iron, manganese, and magnesium sulfates, nitrates, carbonates, and double salts thereof (component 4); oxycarboxylic acids, carboxylic acids, and the like; at least one selected from the group consisting of salts of
A medical waste sterilization treatment agent containing seeds (component 5).
、 成分１と成分２の重量比が１：９９〜９９：１であり、
成分１と成分２の重量の和と成分３の重量との比が１０
０：３〜１：３４、成分１〜３の重量の和と成分４の重
量との比が前者１００に対して後者２０以下、成分１〜
４の重量の和と成分５の重量との比が前者１００に対し
て後者１０以下である医療廃棄物滅菌用処理剤。(6) In the treatment agent for medical waste sterilization according to claim 5, the weight ratio of component 1 to component 2 is 1:99 to 99:1,
The ratio of the sum of the weights of component 1 and component 2 to the weight of component 3 is 10
0:3 to 1:34, the ratio of the sum of the weights of components 1 to 3 to the weight of component 4 is 100 for the former and 20 or less for the latter, components 1 to 3
A treatment agent for medical waste sterilization, wherein the ratio of the sum of the weights of component 4 and the weight of component 5 is 100 for the former and 10 or less for the latter.
反応を起こし、これらの反応による反応熱とアルカリ性
とにより医療廃棄物を滅菌することを特徴とする医療廃
棄物の滅菌処理方法。(7) Sterilization treatment of medical waste, characterized by causing a reaction between the treatment agent for medical waste sterilization according to claim 1 and water, and sterilizing the medical waste by the reaction heat and alkalinity resulting from this reaction. Method.
反応を起こし、これらの反応による反応熱とアルカリ性
とにより医療廃棄物を滅菌することを特徴とする医療廃
棄物の滅菌処理方法。(8) Sterilization treatment of medical waste, characterized by causing a reaction between the treatment agent for medical waste sterilization according to claim 2 and water, and sterilizing the medical waste by the reaction heat and alkalinity resulting from this reaction. Method.
反応を起こし、これらの反応による反応熱とアルカリ性
とにより医療廃棄物を滅菌することを特徴とする医療廃
棄物の滅菌処理方法。(9) Sterilization treatment of medical waste, characterized by causing a reaction between the treatment agent for medical waste sterilization according to claim 3 and water, and sterilizing the medical waste by the reaction heat and alkalinity resulting from this reaction. Method.
の反応を起こし、これらの反応による反応熱とアルカリ
性とにより医療廃棄物を滅菌することを特徴とする医療
廃棄物の滅菌処理方法。(10) Sterilization treatment of medical waste, characterized by causing a reaction between the treatment agent for medical waste sterilization according to claim 4 and water, and sterilizing the medical waste by the reaction heat and alkalinity resulting from this reaction. Method.
の反応を起こし、これらの反応による反応熱とアルカリ
性とにより医療廃棄物を滅菌することを特徴とする医療
廃棄物の滅菌処理方法。(11) Sterilization treatment of medical waste, characterized by causing a reaction between the treatment agent for medical waste sterilization according to claim 5 and water, and sterilizing the medical waste by the reaction heat and alkalinity resulting from this reaction. Method.
の反応を起こし、これらの反応による反応熱とアルカリ
性とにより医療廃棄物を滅菌することを特徴とする医療
廃棄物の滅菌処理方法。(12) A sterilization treatment for medical waste, characterized by causing a reaction between the treatment agent for medical waste sterilization according to claim 6 and water, and sterilizing the medical waste by the reaction heat and alkalinity resulting from this reaction. Method.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP32224489A JPH03181407A (en) | 1989-12-12 | 1989-12-12 | Agent and method for sterilizing medical waste |
| EP19900304112 EP0393992A3 (en) | 1989-04-17 | 1990-04-17 | Device, agent and process for medical waste sterilization |
| US07/983,609 US5248486A (en) | 1989-04-17 | 1992-11-30 | Device, agent and process for medical waste sterilization |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP32224489A JPH03181407A (en) | 1989-12-12 | 1989-12-12 | Agent and method for sterilizing medical waste |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH03181407A true JPH03181407A (en) | 1991-08-07 |
Family
ID=18141518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP32224489A Pending JPH03181407A (en) | 1989-04-17 | 1989-12-12 | Agent and method for sterilizing medical waste |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH03181407A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100766400B1 (en) * | 2007-04-04 | 2007-10-12 | 주식회사 아이파워 | Steam Sterilization Composition and Steam Sterilization Pack |
| JP2008069136A (en) * | 2006-09-15 | 2008-03-27 | Yoshizawa Lime Industry | Sanitary treatment agent containing quicklime as an active ingredient and disinfection and sterilization method using the same |
-
1989
- 1989-12-12 JP JP32224489A patent/JPH03181407A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008069136A (en) * | 2006-09-15 | 2008-03-27 | Yoshizawa Lime Industry | Sanitary treatment agent containing quicklime as an active ingredient and disinfection and sterilization method using the same |
| KR100766400B1 (en) * | 2007-04-04 | 2007-10-12 | 주식회사 아이파워 | Steam Sterilization Composition and Steam Sterilization Pack |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105481044A (en) | Efficient sewage treating tablets and preparation method thereof | |
| KR950010898A (en) | Sterilization of Recombinant Human Serum Albumin Pharmaceutical Formulations | |
| JPH03181407A (en) | Agent and method for sterilizing medical waste | |
| Chen et al. | A novel root‐end filling material based on hydroxyapatite, tetracalcium phosphate and polyacrylic acid | |
| Basu et al. | Osteomyelitis following a haematoma block | |
| CN109013675A (en) | A method of it repairs containing lead-contaminated soil | |
| JPH0386171A (en) | Exothermic agent for sterilizing treatment of medical treatment waste | |
| Declercq et al. | Salmonella typhi osteomyelitis | |
| JPH02274256A (en) | Sterilization treatment method of medical wastes | |
| CN104000958A (en) | External application ointment for treating panaritium and preparing method of external application ointment | |
| Krokhicheva et al. | Zn-Doped Calcium Magnesium Phosphate Bone Cements Based on Struvite and Their Antibacterial Properties | |
| JP7755733B2 (en) | Improved sterilization-solidification method for pathogenic medical waste disposal | |
| JPH0531163A (en) | Treatment of liquid medical waste | |
| JP4718420B2 (en) | Fluorine collecting material and water purification method using the same | |
| JPH0663082A (en) | Treatment of medical treatment waste | |
| EP4210773A1 (en) | Flocculant based disinfection process for pathogenic medical waste disposal | |
| US20250235577A1 (en) | Disinfection and in situ flocculation-solidification process for pathogenic medical waste disposal | |
| EP0393992A2 (en) | Device, agent and process for medical waste sterilization | |
| KR20150115183A (en) | The composition of high purity dental cement and manufacture method of it | |
| JPH02107388A (en) | Biological waste treatment using far infrared ray radiating ceramics and its apparatus | |
| JP2659462B2 (en) | Method and apparatus for sterilizing medical waste | |
| JPH08168507A (en) | Treatment of blood coagulating agent | |
| Kothandam et al. | Dual-Functional Akermanite from Waste Biomass: Combining Mechanical Strength and Biocompatibility for Bone Repair | |
| JP4360868B2 (en) | Hazardous heavy metal collector and hazardous heavy metal collection method | |
| Behairy et al. | Comparative Studies Between Oxide Glass and Glass Ionomer Cement |